Patents Examined by Jennifer Dunston
  • Gene expression signature for classification of kidney tumors
    Patent number: 9068232
    Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: June 30, 2015
    Assignees: Rosetta Genomics Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.
    Inventors: Nitzan Rosenfeld, Yael Spector, Eddie Friedman, Zohar Dotan, Shai Rosenwald
  • Gem-difluorinated C-isopropylgalactoside derivates
    Patent number: 9062313
    Abstract: The present invention concerns compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, in which R represents H, OH or OR19, as well as processes for preparing these compounds and their use as inducer for the transcription of genes under control of the lac promoter.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: June 23, 2015
    Assignee: TFCHEM
    Inventors: Géraldine Deliencourt-Godefroy, Hyacinthe Fillon
  • Heat-resistant newcastle disease virus live vaccine vector system and use thereof
    Patent number: 9051584
    Abstract: A heat-resistant NDV live vaccine vector system includes a transcription plasmid, three helper plasmids, and host cells. The transcription plasmid is constructed by through cloning complete genomic cDNA of a heat-resistant NDV vaccine strain to a pBR322 vector. The three helper plasmids are constructed by cloning sequences coding nucleoprotein (NP), phosphoprotein, large polymerase protein of a heat-resistant NDV vaccine strain respectively to pcDNA3.1 vectors. A recombinant NDV artificially obtained by cotransfacting host cells with the transcription plasmid and the three helper plasmids shows heat-resistance.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: June 9, 2015
    Assignee: INSTITUTE OF ANIMAL HUSBANDRY AND VETERINARY SCIENCES, HUBEI ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Guoyuan Wen, Huabin Shao, Jun Yang, Honglin Wang, Qingping Luo, Rongrong Zhang, Diyun Ai, Ling Luo, Yu Shang, Jing Guo, Chen Chen
  • Post-transcriptional gene silencing using expressed double stranded RNA
    Patent number: 9051566
    Abstract: Described herein are methods for identifying nucleic acid sequences that modulate the function of a cell, the expression of a gene in a cell, or the biological activity of a target polypeptide in a cell. The methods involve the use of double stranded RNA expression libraries, double stranded RNA molecules, and post-transcriptional gene silencing techniques.
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: June 9, 2015
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Tony Giordano, Catherine Pachuk, Chandrasekhar Satishchandran
  • Markers for endometrial cancer
    Patent number: 9046522
    Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: June 2, 2015
    Assignee: Geadic Biotec, AIE
    Inventors: Miguel Abal Posada, Andreas Doll, Antonio Gil Moreno, Tamara Maes, Cristina Perez, Jaume Reventós Puigjaner, Elisabet Rossell
  • Agents for reversing epigenetic silencing of genes
    Patent number: 9034574
    Abstract: The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: May 19, 2015
    Assignee: The Johns Hopkins University
    Inventors: William G. Nelson, Srinivasan Yegnasubramanian, Xiaohui Lin, Traci J. Speed, Zachery Reichert
  • MUTZ-3 dendritic cells
    Patent number: 9029143
    Abstract: The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and test systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: May 12, 2015
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Rik J. Scheper, Alan Masterson, Herbert M. Pinedo
  • Recombinant pokeweed antiviral proteins, compositions and methods related thereto
    Patent number: 9023596
    Abstract: The present invention provides novel, modified pokeweed antiviral proteins, nucleic acids that encode the proteins, conjugates that incorporate the proteins, and methods to make and use the proteins. The present invention also provides methods to administer the conjugates to animals, for the purpose of directing toxin to particular cells.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: May 5, 2015
    Assignees: Colorado State University Research Foundation, Cedus, Inc.
    Inventors: Eric R. Weber, Torrance M. Nett
  • Modular DNA-binding domains and methods of use
    Patent number: 9017967
    Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: April 28, 2015
    Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
  • Topical administration of NF-kappaB decoy to treat atopic dermatitis
    Patent number: 9012417
    Abstract: A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-?B decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-?B decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: April 21, 2015
    Assignee: Anges MG, Inc.
    Inventors: Ryuichi Morishita, Motokuni Aoki, Toshio Ogihara, Yasufumi Kaneda, Hiroshige Nakamura
  • Systems and methods for measuring translation activity in viable cells
    Patent number: 9012171
    Abstract: Systems for measuring protein translation and methods for measuring overall translation activity in viable cells or subcellular compartments is disclosed. The methods identify general ribosomal activity, if desired at sub-cellular resolution, thereby providing a signal indicating the rate of any of the steps of protein synthesis selected from initiation, elongation, termination or recycling. The translation system can be used to identify translation modulators in high-throughput-screening (HTS).
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: April 21, 2015
    Assignee: Anima Cell Metrology, Inc.
    Inventor: Ze'ev Smilansky
  • Methods for evaluating ribonucleotide sequences
    Patent number: 9012150
    Abstract: Methods for identifying ribonucleotide sequences, in vitro, using the ribosome-mediated translation, are provided.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: April 21, 2015
    Assignee: Anima Cell Metrology
    Inventor: Ze'ev Smilansky
  • Manufacturing three-dimensional scaffolds using electrospinning at low temperatures
    Patent number: 9011754
    Abstract: The present invention refers to an apparatus and a method for the manufacture of a three-dimensional scaffold at low temperatures and the respective use of this method and apparatus.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: April 21, 2015
    Assignee: Nanyang Technological University
    Inventors: Meng Fatt Leong, Tze Chiun Lim, Kerm Sin Chian
  • Targeted genomic modification with partially single-stranded donor molecules
    Patent number: 9005973
    Abstract: Disclosed herein are donor molecules comprising single-stranded complementary regions flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: April 14, 2015
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Gregory J. Cost, Dmitry M. Guschin, Fyodor Urnov
  • Polymeric carrier
    Patent number: 9006193
    Abstract: Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: April 14, 2015
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • EGFR-homing double-stranded RNA vector for systemic cancer treatment
    Patent number: 9006406
    Abstract: An epidermal growth factor receptor (EGFR)-homing vector comprising a double-stranded RNA (dsRNA) molecule with an EGFR-binding peptide or polypeptide, is disclosed for use in combination with immune cells for treatment of cancer overexpressing EGFR.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: April 14, 2015
    Inventors: Alexander Levitzki, Alexei Shir
  • Vector comprising multiple homologous nucleotide sequences
    Patent number: 8999637
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: April 7, 2015
    Assignee: Bavarian Nordic A/S
    Inventor: Robin Steigerwald
  • Methods for treating spinal muscular atrophy
    Patent number: 8986935
    Abstract: Described herein are methods for the identification or validation of compounds capable of causing ribosomal frameshifting and the use of the compounds identified by the methods described herein to produce a stabilized SMN?Ex7 protein and treat Spinal Muscular Atrophy.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: March 24, 2015
    Assignee: PTC Therapeutics, Inc.
    Inventors: Sergey V. Paushkin, Nikolai A. Naryshkin, Ellen Welch
  • Selective inhibitors of translesion DNA replication
    Patent number: 8981078
    Abstract: An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in FIG. 1.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 17, 2015
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee, Xuemei Zhang
  • Regulatory elements
    Patent number: 8975391
    Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 10, 2015
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Barbara Enenkel